Skip to main content
. 2017 Jan 24;61(2):e01964-16. doi: 10.1128/AAC.01964-16

TABLE 3.

Characteristics of patients with carbapenem-resistant infections treated with compassionate-use CAZ-AVI

Characteristic Value (n = 38)a
Demographic characteristics
    Age in yr, median (IQRb) 61 (47–67)
    Male sex 25 (65.8)
    Location before hospitalization
        Home 33 (86.8)
        Transferred from another hospital 5 (13.2)
    Comorbidities
        Transplant recipient 5 (13.2)
        Diabetes mellitus 8 (21.1)
        Immunosuppressionc 10 (26.3)
        Renal disease 7 (18.4)
        Cardiovascular disease 11 (28.9)
    McCabe score of >1 19 (50.0)
Infection characteristics
    Organism and carbapenemase
        Klebsiella pneumoniae
            KPC 22
            OXA-48 12
        Klebsiella oxytoca (KPC) 1
        Escherichia coli (OXA-48) 1
        Pseudomonas aeruginosa 2
    Hospital-acquired infection 34 (89.5)
    Bacteremia 26 (68.4)
    Polymicrobial infection 11 (29.0)
    Life-threatening infection (high risk of death within 30 days) 23 (60.5)
Antibiotics before CAZ-AVI
    Received antibiotics before CAZ-AVI for this infection 36 (94.7)
    Days of antibiotic treatment before CAZ-AVI, median (IQR) 13 (7–31)
    No. of antibiotics before CAZ-AVI, median (IQR) 3 (3–4)
Other treatments before CAZ-AVI
    Surgery to remove the source of infection 16 (42.1)
    Removal of foreign body involved in infection 9 (23.7)
Clinical status at start of CAZ-AVI treatment
    Mechanical ventilation 14 (36.8)
    Vasopressor support 17 (44.7)
    Unconscious 12 (31.6)
CAZ-AVI treatment
    Days of treatment, median (IQR) 16 (14–21)
    Extended infusion 36 (94.7)
    Concurrent antibiotic treatmentd 25 (65.8)
    Received standard CAZ-AVI dose 24 (63.2)
a

Values are number (%) of patients unless indicated otherwise.

b

IQR, interquartile range.

c

Immunosuppression was defined as posttransplant, chemotherapy in past 6 weeks, systemic steroids (>20 mg of prednisone) or other immunosuppressive agents in past 2 weeks, absolute neutrophil count of <500/μl, or HIV/AIDS.

d

During CAZ-AVI treatment, patient received another antibiotic to which organism was nonresistant in vitro.